Cerebrospinal Fluid Cytokines and Neurotrophic Factors in Human Chronic Pain Populations: A Comprehensive Review

Pain Practice ◽  
2014 ◽  
Vol 16 (2) ◽  
pp. 183-203 ◽  
Author(s):  
Martin F. Bjurstrom ◽  
Sarah E. Giron ◽  
Charles A. Griffis
2020 ◽  
Author(s):  
Weiling Liu ◽  
Chunmei Li ◽  
Francis Chee Kuan Tan ◽  
Hong Jye Neo ◽  
Yiong Huak Chan ◽  
...  

Abstract Background Chronic osteoarthritic pain is not well understood in terms of its pathophysiological mechanism. Activated glial cells are thought to play a role in the maintenance of chronic pain. T98G glioblastoma cell line was previously observed to release higher amounts of interleukin-6 (IL-6) when treated with cerebrospinal fluid (CSF) from patients with another chronic pain condition, post-herpetic neuralgia. In this study, we investigated the ability of CSF from patients diagnosed with knee osteoarthritis suffering from chronic pain, to trigger the release of pro-inflammatory cytokines, IL-6, IL-1beta and tumour necrosis factor alpha (TNF-α) from T98G. Characterization of upstream signalling was also explored. Methods 15 osteoarthritis patients undergoing total knee replacement due to chronic knee pain and 15 patients without pain undergoing other surgeries with spinal anaesthesia were prospectively recruited. CSF was collected during anaesthesia. CSF were added to cultured T98G cells in the presence of lipopolysaccharide. IL-6, IL-1β and TNF-α release from T98G cells were measured using enzyme immunoassay. Antibody array and western blotting were performed using CSF-triggered T98G cell lysates to identify possible signalling targets. Age, gender and pain scores were recorded. Mann-Whitney U test was used to compare IL-6 release and protein expression between groups. Association between IL-6 and pain score was analysed using linear regression. Results Significant higher levels of IL-6 were released by T98G cells when induced by osteoarthritis patients' CSF in presence of lipopolysaccharide. IL-6 levels showed positive association with pain score (adjusted B estimate= 10.1 (95% Confidence Interval 4.3-15.9); p= 0.001). Antibody array conducted with 6 pooled T98G cell lysate induced with osteoarthritis pain patient CSF identified greater than 2-fold proteins including STE20-related kinase adaptor protein and spleen tyrosine kinase. Further validation done using western blotting of individual CSF-triggered T98G cell lysate showed non-significant increase. Conclusion Higher IL-6 release from T98G when triggered by OA CSF, in the presence of lipopolysaccharide, suggest presence of "unknown molecule" in CSF that may be crucial in the maintenance phase of chronic pain in our osteoarthritis population. Further studies on the signalling pathways involved in pain and relevance of IL-6 release from T98G in other pain models are needed.


2019 ◽  
Vol 33 (4) ◽  
pp. 465-486
Author(s):  
Alan David Kaye ◽  
Mark W. Motejunas ◽  
Lauren A. Bonneval ◽  
Ken P. Ehrhardt ◽  
Dustin R. Latimer ◽  
...  

2020 ◽  
Vol 9 (1) ◽  
pp. 129-142
Author(s):  
Ivan Urits ◽  
Daniel Smoots ◽  
Lekha Anantuni ◽  
Prudhvi Bandi ◽  
Katie Bring ◽  
...  

2016 ◽  
Vol 224 ◽  
pp. 69-76 ◽  
Author(s):  
Prashanth Manda ◽  
Avadhesh Singh Kushwaha ◽  
Santanu Kundu ◽  
H.N. Shivakumar ◽  
Seong Bong Jo ◽  
...  

2020 ◽  
Vol 34 (3) ◽  
pp. 449-461
Author(s):  
Kyle Gress ◽  
Karina Charipova ◽  
Jai Won Jung ◽  
Alan D. Kaye ◽  
Antonella Paladini ◽  
...  

Peptides ◽  
1997 ◽  
Vol 18 (7) ◽  
pp. 923-927 ◽  
Author(s):  
D.M Sundblom ◽  
E Kalso ◽  
I Tigerstedt ◽  
K Wahlbeck ◽  
P Panula ◽  
...  

2015 ◽  
Vol 16 (5) ◽  
pp. 436-444 ◽  
Author(s):  
Alexandre J. Parent ◽  
Nicolas Beaudet ◽  
Kathya Daigle ◽  
Robert Sabbagh ◽  
Yanick Sansoucy ◽  
...  

2012 ◽  
Vol 3S;15 (3S;7) ◽  
pp. ES157-ES168 ◽  
Author(s):  
Daniel Krashin

Background: Human Immunodeficiency Virus (HIV) patients have an increased rate of chronic pain, particularly peripheral neuropathy. This disease burden causes considerable disability and negatively affects quality of life. Pain is undertreated and more complex to manage in these patients for a number of reasons, including complex anti-retroviral drug regimens, higher risks of side effects, and higher rates of comorbid psychiatric illness and substance abuse. Pain management must take these factors into account and use all available modalities, including nonopioid pain relievers, adjuvant medications, and psychosocial therapies in addition to opioid analgesics. Here we review recent recommendations regarding acute and chronic opioid treatment of pain and the treatment of opioid dependence in HIV-infected patients, and provide suggestions regarding aberrant behavior in pain treatment. Objectives: The objective of this comprehensive review is to assess and summarize the complicating factors involved in treating HIV patients’ pain with opioid analgesics. Study Design: This is a narrative review without a systematic quality assessment of the literature discussion. Methods: A comprehensive review of the literature relating to pain and pain treatment in HIV patients. The literature was collected from electronic databases, textbooks, and other sources. The scientific literature reviewed includes randomized trials, observational studies, systematic reviews, guidelines, and government reports. Results: This patient population is heterogeneous and diverse in their medical issues and comorbidities, but a systematic, stepwise approach to assessing and managing pain in HIV patients is described. Chronic opioid treatment has proven to be problematic and considerations and alternatives to this treatment are described. Management of pain in patients with opioid addiction, a frequent comorbidity of HIV infection, requires special awareness and different prescribing practices. Screening and identifying patients who are at special risk for developing medical or behavior complications of pain treatment is essential, and approaches to this, and common forms of aberrant behavior, are described. Limitations: The scientific literature on opioid treatment in this population is limited. The population of HIV patients is heterogeneous and differs in significant ways based on ethnicity, national origin, and mode of transmission, making it difficult to generalize about pain treatment in such a diverse group. Conclusions: Pain management in HIV patients must take these factors into account and use all available modalities for treatment, including nonopioid analgesics, adjuvant medications, and psychosocial therapies. Opioid analgesics should be prescribed with caution in accordance with current guidelines and after careful risk assessment. Key words: HIV, Human Immunodeficiency Virus, acute pain, chronic pain, psychiatric comorbidity, opioid dependence, opioids, chronic opioid therapy, substance abuse.


Sign in / Sign up

Export Citation Format

Share Document